ACAAI: Considerable delay seen from Rx to approval for children's… | HappeningNow.news

Health · 3 views

ACAAI: Considerable delay seen from Rx to approval for children's biologics

There is a considerable delay from prescription of biologic therapy to final approval for pediatric patients, and almost 40% of prescriptions requiring a prior authorization (PA) are denied, according to a study presented at the annual…

Source Summary Published 47m ago Brief Under 1 min brief
Story intelligence
Coverage Single outlet Single-outlet story
Views 3 Community interest
Brief read Under 1 min brief 54 words

Summary

There is a considerable delay from prescription of biologic therapy to final approval for pediatric patients, and almost 40% of prescriptions requiring a prior authorization (PA) are denied, according to a study presented at the annual meeting of the American College of Allergy, Asthma and Immunology, held from Nov. 12 to 16 in Phoenix.

Read original at Medical Xpress

More from Health

Continue reading recent Health coverage

Support HappeningNow

Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.

Support HappeningNow

Report an issue with this page